Why is Genocea Biosciences Inc (GNCA) Stock Up This Morning?

Share

Genocea Biosciences Inc (NASDAQ:GNCA) shares are trading up significantly in early morning trading. Shares are trading at $6.86 each, up over 7% from yesterday’s closing price of $6.43.

There are several reasons for today’s large jump. One of which is the fact that UBS initiated coverage on Genocea Biosciences Inc (NASDAQ:GNCA) with a positive buy rating and a price target of $15.00. Additionally , CEO of Genocea Biosciences Inc (NASDAQ:GNCA), William D. Clark, purchased 3,800 shares of company stock totally $24,510 in value ($6.45 per share). This all points in a positive direction for the company.

The stock closed at $6.43 during the last trading session. It is down 32.03% since May 14, 2015 and is downtrending. It has underperformed the S&P500 by 29.41%.

From a total of 2 analysts covering Genocea Biosciences (NASDAQ:GNCA) stock, 2 rate it a “Buy”, 0 a “Sell”, and 0 a “Hold”. This means that 100% of the ratings are positive. The highest target price is $22 while the lowest target price is $15. The mean of all analyst targets is $17 which is 164.39% above today’s ($6.43) stock price. Genocea Biosciences was the topic of 4 analyst reports since August 6, 2015 according to the firm StockzIntelligence Inc. Needham maintained shares on October 20 with a “Buy” rating. Piper Jaffray maintained GNCA stock in a recent report from August 6 with a “Overweight” rating.

Genocea Biosciences, Inc. is a biopharmaceutical company. The company has a market cap of $180.78 million. The Firm discovers and develops vaccines and immunotherapies to address diseases with unmet needs. It currently has negative earnings. It uses its discovery platform, AnTigen Lead Acquisition System , to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses, in contrast to approved vaccines and immunotherapies, which are designed to act primarily through B cell (or antibody) immune responses.

COMMENTS: